Viral kinetic modeling: state of the art

J Pharmacokinet Pharmacodyn. 2014 Oct;41(5):431-43. doi: 10.1007/s10928-014-9363-3. Epub 2014 Jun 25.

Abstract

Viral kinetic (VK) modeling has led to increased understanding of the within host dynamics of viral infections and the effects of therapy. Here we review recent developments in the modeling of viral infection kinetics with emphasis on two infectious diseases: hepatitis C and influenza. We review how VK modeling has evolved from simple models of viral infections treated with a drug or drug cocktail with an assumed constant effectiveness to models that incorporate drug pharmacokinetics and pharmacodynamics, as well as phenomenological models that simply assume drugs have time varying-effectiveness. We also discuss multiscale models that include intracellular events in viral replication, models of drug-resistance, models that include innate and adaptive immune responses and models that incorporate cell-to-cell spread of infection. Overall, VK modeling has provided new insights into the understanding of the disease progression and the modes of action of several drugs. We expect that VK modeling will be increasingly used in the coming years to optimize drug regimens in order to improve therapeutic outcomes and treatment tolerability for infectious diseases.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Antiviral Agents / pharmacokinetics*
  • Antiviral Agents / pharmacology*
  • Antiviral Agents / therapeutic use
  • Computer Simulation*
  • Disease Progression
  • Hepatitis C / drug therapy*
  • Hepatitis C / immunology
  • Hepatitis C / virology*
  • Humans
  • Influenza, Human / drug therapy*
  • Influenza, Human / immunology
  • Influenza, Human / virology*
  • Models, Biological

Substances

  • Antiviral Agents